摘要
目的初步探讨炎症性肠病(IBD)患者巯基嘌啉甲基转移酶(TPMT)基因突变情况,了解硫唑嘌啉的不良反应。方法对30例我院住院IBD患者TPMT*3C基因型通过基因PCR扩增、基因测序的方法进行检测,其中10例患者给予硫唑嘌啉1～2 mg/kg.d-1剂量口服。结果 30例患者TPMT*3C基因型均为野生型,未发现基因突变,2例发生不良反应。结论 TPMT*3C在IBD中突变率较低;应用硫唑嘌啉需严密观察其不良反应。
Objective To investigate the thiopurine S-methyltransferase（TPMT） genotype and azathioprine-related ad- verse drug reactions in patients with inflammatory bowel disease （IBD）. Methods 30 patient with IBD in our hospital were en- rolled, and TPMT ＊ 3C genotype was detected by PCR and sequencing. 10 out of 30 patients were treated with azathioprine 1.0 - 2.0 mg/kg . d^-1. Results All patients TPMT ＊ 3 C genotype were wild genotype, no mutation was detected. Azathioprine toxici- ty occurred in 2 patients. Conclusion The mutation rate of TPMT ＊ 3 C is lower and it is necessary to monitor azathioprine tox- icity among trentment.
出处
《临床消化病杂志》
2012年第4期202-203,207,共3页
Chinese Journal of Clinical Gastroenterology
关键词
炎症性肠病
硫唑嘌啉甲基转移酶
不良反应
Inflammatory bowel disease
Thiopurine S-methyltransferase
Adverse drug reactions
